World
Chinese Drugmaker in Talks to Test Virus Vaccine Globally
- Sinovac plans to do trials in regions with uncurbed spread
- Vaccine’s efficacy to be determined where disease occurs: CEO
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
The drugmaker behind one of China’s most promising coronavirus vaccine candidates is in talks to conduct late-stage trials globally as the race for immunization against Covid-19 intensifies.
Beijing-based Sinovac Biotech Ltd. is in discussion with regulators in other countries, and the World Health Organization, to launch phase III clinical trials in regions where the novel coronavirus is still spreading rapidly, CEO Yin Weidong said in an interview Thursday.